贝前列素钠对糖尿病肾病腹膜透析患者腹膜超滤功能的影响  

Effect of beraprost on peritoneal ultrafiltration function in patients with diabetic nephropathy undergoing peritoneal dialysis

作　　者：胡国强[1] 钟雪莺[1] 石晓峰[1] 轩慧杰[1] 邱创业 张艳霞 HU Guo-qiang;ZHONG Xue-ying;SHI Xiao-feng;XUAN Hui-jie;QIU Chuang-ye;ZHANG Yan-xia(Department of Nephrology, Jiangmen Central Hospital, Jiangmen 529000, China)

机构地区：[1]广东省江门市中心医院肾内科

出　　处：《广东医科大学学报》2019年第4期396-398,共3页Journal of Guangdong Medical University

摘　　要：目的观察贝前列素钠对糖尿病肾病腹膜透析(PD)患者腹膜超滤功能的影响。方法60例糖尿病肾病PD患者分别给予参芎注射液(对照组)或贝前列素钠(试验组)治疗1个月,比较两组生化指标、腹膜透析相关指标和癌抗原125(CA125)水平差异。结果治疗后两组患者的超滤量和腹膜透出液中CA125水平均高于治疗前(P<0.01),但两组间差异无统计学意义(P>0.05)。结论贝前列素钠可改善糖尿病肾病PD患者腹膜超滤功能。Objective To observe the effect of beraprost on peritoneal ultrafiltration function in patients with diabetic nephropathy (DN) undergoing peritoneal dialysis (PD). Methods Sixty DN cases undergoing PD were treated with Shenxiong injection (control group) or beraprost (experiment group) for 1 month. Biochemical indices, PD-related parameters, and cancer antigen 125 (CA125) level were compared between two groups. Results Ultrafiltration volume and dianeal CA125 level were increased posttreatment compared with pretreatment (P<0.01), but they were insignificant between two groups (P>0.05). Conclusion Beraprost can improve peritoneal ultrafiltration function in DN patients undergoing PD.

关 键 词：贝前列素钠 糖尿病肾病 腹膜透析 

分 类 号：R692.5[医药卫生—泌尿科学]